Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A
Completed · Phase 4 · NCT05466539
Conditions: Compartment Syndrome of Leg
At a glance
- Research payments reported, 2025
- $4,403
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 3
About the trial
- Sponsor
- Emory University (with Ipsen)
- Tested
- AbobotulinumtoxinA (drug), Placebo (drug)
- Dates
- Started 2024-04-25; completion 2025-08-13
- Results posted
- Not yet
Chronic Exertional Compartment Syndrome (CECS) is a painful condition affecting runners and it is caused by a reversible increase in pressure within a closed compartment in the leg. Currently, to diagnose CECS, a large needle is placed into the muscle to measure pressure, which is invasive and painful. After diagnosis, the gold standard of treatment is surgery, which is also invasive, involves a prolonged return to play, and has a significant number of treatment failures. A growing literature has suggested alternative methods to both diagnosis and treatment that include the use of ultrasound to investigate muscle stiffness with shear wave elastography (SWE), and treatment with botulinum t…
From ClinicalTrials.gov, last updated 2025-10-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $4,403 in research payments for this study in 2025 (1 payments).
Products named: Dysport
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.